BR112015031903A8 - composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto - Google Patents

composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto Download PDF

Info

Publication number
BR112015031903A8
BR112015031903A8 BR112015031903A BR112015031903A BR112015031903A8 BR 112015031903 A8 BR112015031903 A8 BR 112015031903A8 BR 112015031903 A BR112015031903 A BR 112015031903A BR 112015031903 A BR112015031903 A BR 112015031903A BR 112015031903 A8 BR112015031903 A8 BR 112015031903A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
compounds
Prior art date
Application number
BR112015031903A
Other languages
English (en)
Other versions
BR112015031903A2 (pt
Inventor
Chow Maneval Edna
H Hager Jeffrey
Kahraman Mehmet
D Smith Nicholas
P Govek Steven
Original Assignee
Seragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015031903(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seragon Pharmaceuticals Inc filed Critical Seragon Pharmaceuticals Inc
Publication of BR112015031903A2 publication Critical patent/BR112015031903A2/pt
Publication of BR112015031903A8 publication Critical patent/BR112015031903A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo “composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto” a presente invenção se refere aos compostos que são moduladores do receptor de estrogênio. a presente invenção também se refere às composições e medicamentos farmacêuticos que incluem os compostos descritos no presente, bem como aos métodos de utilização de tais moduladores do receptor de estrogênio, isoladamente e em combinação com outros compostos, para o tratamento de doenças ou condições que são mediadas ou dependentes dos receptores de estrogênio.
BR112015031903A 2013-06-19 2014-06-18 composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto BR112015031903A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836901P 2013-06-19 2013-06-19
US201461952430P 2014-03-13 2014-03-13
PCT/US2014/043040 WO2014205138A1 (en) 2013-06-19 2014-06-18 Estrogen receptor modulator and uses thereof

Publications (2)

Publication Number Publication Date
BR112015031903A2 BR112015031903A2 (pt) 2017-07-25
BR112015031903A8 true BR112015031903A8 (pt) 2019-12-31

Family

ID=52105249

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031903A BR112015031903A8 (pt) 2013-06-19 2014-06-18 composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto

Country Status (20)

Country Link
US (2) US9873684B2 (pt)
EP (1) EP3010501B1 (pt)
JP (2) JP6576916B2 (pt)
KR (1) KR20160021277A (pt)
CN (1) CN105324115B (pt)
AU (1) AU2014281511A1 (pt)
BR (1) BR112015031903A8 (pt)
CA (1) CA2912853A1 (pt)
CL (1) CL2015003456A1 (pt)
CR (1) CR20150664A (pt)
EA (1) EA031077B1 (pt)
HK (1) HK1214532A1 (pt)
IL (1) IL242611B (pt)
MX (1) MX2015017655A (pt)
PE (1) PE20160157A1 (pt)
PH (1) PH12015502621A1 (pt)
SG (1) SG11201509508YA (pt)
TW (1) TW201501710A (pt)
UA (1) UA117249C2 (pt)
WO (1) WO2014205138A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
CN105451735B (zh) 2013-06-19 2019-01-11 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
EA031077B1 (ru) * 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
EP2862880A1 (en) 2013-10-16 2015-04-22 Solvay Acetow GmbH Acylation process
KR20160124909A (ko) * 2014-03-13 2016-10-28 에프. 호프만-라 로슈 아게 에스트로겐 수용체 조절제를 함유하는 치료 조합물
US9855270B2 (en) 2014-03-13 2018-01-02 Genentech, Inc. Methods and compositions for modulating estrogen receptor mutants
RS59430B1 (sr) 2014-03-13 2019-11-29 Univ Indiana Res & Tech Corp Alosterni modulatori proteina jezgra hepatitisa b
EP3233818A1 (en) * 2014-12-18 2017-10-25 F. Hoffmann-La Roche AG Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN107108611B (zh) 2014-12-18 2020-09-25 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
UA120882C2 (uk) 2015-05-29 2020-02-25 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Тетразаміщені алкенові сполуки і їх застосування
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
TW201720802A (zh) 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
SI3355884T1 (sl) 2015-10-01 2021-11-30 Olema Pharmaceuticals, Inc. Antiestrogenska zdravila tetrahidro-1H-pirido(3,4-b)indola
PT3368519T (pt) 2015-10-27 2022-05-25 Sun Pharma Advanced Res Co Ltd Novos antiestrogénios heterocíclicos
CA3008020C (en) 2015-12-09 2024-02-20 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454862A4 (en) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
TW201815789A (zh) 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
AU2017326356A1 (en) 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CN109843888B (zh) 2016-10-24 2022-03-01 阿斯利康(瑞典)有限公司 可用于治疗癌症的6，7，8，9-四氢-3H-吡唑并[4，3-f]异喹啉衍生物
MX2019005144A (es) * 2016-11-04 2019-10-14 Genentech Inc Tratamiento de cáncer de mama positivo para her2.
AU2017363699B2 (en) 2016-11-28 2021-02-18 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
CN110177554B (zh) 2017-01-06 2023-06-02 G1治疗公司 用于治疗癌症的组合疗法
US10221173B2 (en) 2017-01-30 2019-03-05 Astrazeneca Ab Chemical compounds
WO2018148440A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
TW201835064A (zh) 2017-02-10 2018-10-01 美商G1治療公司 苯并噻吩雌激素受體調節劑
EP3589630B1 (en) 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
AU2018236188B2 (en) 2017-03-13 2022-01-27 Assembly Biosciences, Inc. Process for making hepatitis B core protein modulators
CA3067873A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of g1t38 and methods of manufacture thereof
MX2020004013A (es) 2017-10-18 2021-01-08 Novartis Ag Composiciones y metodos para la degradacion selectiva de proteinas.
CN111315378A (zh) 2017-11-16 2020-06-19 诺华股份有限公司 包含lsz102和瑞博西尼的药物组合
US10695333B2 (en) 2017-12-01 2020-06-30 Novartis Ag Pharmaceutical combination comprising LSZ102 and alpelisib
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
US10954234B2 (en) 2018-06-21 2021-03-23 Genentech, Inc. Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
CA3148592A1 (en) 2019-07-22 2021-01-28 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
DE3684446D1 (de) 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) * 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6262270B1 (en) 1998-08-14 2001-07-17 Schering Corporation Enantioselective synthesis
AU782142B2 (en) 1999-12-07 2005-07-07 Sumitomo Chemical Company, Limited Mutant ERalpha and test systems for transactivation
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1355906B1 (en) 2001-01-24 2005-01-12 CHIESI FARMACEUTICI S.p.A. 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
WO2004091488A2 (en) * 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
MX2012014431A (es) 2010-06-10 2013-02-26 Aragon Pharmaceuticals Inc Modulares del receptor de estrogenos y usos de los mismos.
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
SI2766040T1 (sl) * 2011-10-14 2019-08-30 F. Hoffmann-La Roche Ag Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
BR112014014124A2 (pt) * 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos
CN104220426B (zh) 2012-03-20 2017-03-01 塞拉根制药公司 雌激素受体调节剂及其用途
CA2873882C (en) * 2012-04-05 2020-12-15 Boehringer Ingelheim International Gmbh 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
EP2970130A4 (en) 2013-03-14 2016-08-03 Seragon Pharmaceuticals Inc MODULATORS OF POLYCYCLIC STROGEN RECEPTORS AND USES THEREOF
EA031077B1 (ru) * 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CN105451735B (zh) 2013-06-19 2019-01-11 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
SG11201604501TA (en) 2013-12-06 2016-07-28 Hoffmann La Roche Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
KR20160124909A (ko) 2014-03-13 2016-10-28 에프. 호프만-라 로슈 아게 에스트로겐 수용체 조절제를 함유하는 치료 조합물
US9855270B2 (en) 2014-03-13 2018-01-02 Genentech, Inc. Methods and compositions for modulating estrogen receptor mutants
US9493945B2 (en) 2014-07-18 2016-11-15 Williams Scotsman, Inc. Wall panel connecting system for modular building units
EP3233818A1 (en) 2014-12-18 2017-10-25 F. Hoffmann-La Roche AG Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof

Also Published As

Publication number Publication date
CN105324115A (zh) 2016-02-10
UA117249C2 (uk) 2018-07-10
AU2014281511A1 (en) 2015-12-03
PE20160157A1 (es) 2016-03-18
BR112015031903A2 (pt) 2017-07-25
EP3010501B1 (en) 2021-11-03
JP6576916B2 (ja) 2019-09-18
CA2912853A1 (en) 2014-12-24
EP3010501A1 (en) 2016-04-27
EA031077B1 (ru) 2018-11-30
SG11201509508YA (en) 2015-12-30
MX2015017655A (es) 2016-04-15
JP2016523253A (ja) 2016-08-08
EA201592214A1 (ru) 2016-06-30
TW201501710A (zh) 2015-01-16
EP3010501A4 (en) 2017-02-01
US20160090378A1 (en) 2016-03-31
US20170275273A1 (en) 2017-09-28
HK1214532A1 (zh) 2016-07-29
WO2014205138A1 (en) 2014-12-24
US9873684B2 (en) 2018-01-23
IL242611B (en) 2018-10-31
KR20160021277A (ko) 2016-02-24
CL2015003456A1 (es) 2016-07-29
JP2019142871A (ja) 2019-08-29
US10227334B2 (en) 2019-03-12
CR20150664A (es) 2016-01-29
CN105324115B (zh) 2019-01-04
PH12015502621A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015022566A2 (pt) composto e composição farmacêutica
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
BR112015018882A2 (pt) derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015030387A8 (pt) compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
BR112014011341A2 (pt) composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
EA201501163A1 (ru) Модуляторы рецептора cxcr7
BR112017013998A2 (pt) novos derivados de benzimidazol como agentes anti-histamínicos
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112013025682A2 (pt) Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]